Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

797 ARTÍCULOS , VIENDO DEL 661 AL 675

Understanding Cerebral Blood Flow Dynamics for Alzheimer's Disease Prevention Through Acute Exercise (flADex): Protocol for a Randomized Crossover Trial

Martín-Fuentes I, Fernandez-Gamez B, Vidal-Almela S, Caro-Rus A, Solis-Urra P, Sánchez-Aranda L, Fernández-Ortega J, Sanchez-Martinez J, Coca-Pulido A, Olvera-Rojas M, Barranco-Moreno EJ, Marin-Alvarez JD, Bakker EA, Toval A, Bellón D, Sclafani A, Karikari TK, Erickson KI, Gómez-Río M, Ortega FB, Esteban-Cornejo I.

Brain Behav. 2025 Nov;15(11):e70636. doi: 10.1002/brb3.70636.

Influence of age and sex on presymptomatic phases of neurodegenerative diseases: Focus on multiple sclerosis and Alzheimer's disease

Zeydan B, Kantarci K.

Rev Neurol (Paris). 2025 Nov;181(9):829-838. doi: 10.1016/j.neurol.2025.06.015. Epub 2025 Aug 6.

Examining the role of antioxidant supplementation in mitigating oxidative stress markers in Alzheimer's disease: a comprehensive review

Jawad M, Uthirapathy S, Altalbawy FMA, Oghenemaro EF, Rizaev J, Lal M, Eldesoqui M, Sharma N, Pramanik A, Al-Hamairy AK.

Inflammopharmacology. 2025 Feb;33(2):573-592. doi: 10.1007/s10787-024-01622-9. Epub 2024 Dec 19.

Integrating artificial intelligence with small molecule therapeutics and precision medicine for neurochemical understanding of Alzheimer's diseases

Alshehri ZS.

Neuroscience. 2025 Nov 1;586:44-57. doi: 10.1016/j.neuroscience.2025.08.055. Epub 2025 Sep 18.

Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a 2-Year Phase 2 Trial of APOE4 Carriers with Early Alzheimer's Disease

Hey JA, Yu JY, Abushakra S, Schaefer JF, Power A, Kesslak P, Paul J, Tolar M.

Clin Pharmacokinet. 2025 Mar;64(3):407-424. doi: 10.1007/s40262-025-01482-8. Epub 2025 Feb 5.

Biofluid-based biomarker panels toward personalized medicine in dementia diagnostics

Zetterberg H.

Alzheimers Dement. 2025 Jun;21(6):e70178. doi: 10.1002/alz.70178.

Guidelines for the standardization of pre-analytical variables for salivary biomarker studies in Alzheimer's disease research: An updated review and consensus of the Salivary Biomarkers for Dementia Research Working Group

Ng TKS, Udeh-Momoh C, Lim MA, Gleerup HS, Leifert W, Ajalo C, Ashton N, Zetterberg H, Rissman RA, Winston CN, O' Bryant S, Jenkins R, Carro E, Orive G, Tamburin S, Olvera-Rojas M, Solis-Urra P, Esteban-Cornejo I, Santos GAAD, Rajan KB, Koh D, Simonsen AH, Slowey PD; Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment: Biofluid Based Biomarkers Professional Interest Area Salivary Biomarkers for Dementia Research Working Group (ISTAART‐BBB‐PIA‐SWG).

Alzheimers Dement. 2025 Feb;21(2):e14420. doi: 10.1002/alz.14420. Epub 2024 Dec 30.

Association of dipeptidyl peptidase-4 with Alzheimer's disease: A new therapeutic prospect

Wang X, Chen L, Li W, He Z, Jiang H.

J Alzheimers Dis. 2025 Jan;103(2):319-332. doi: 10.1177/13872877241304673. Epub 2025 Jan 8.

Disclosure of plasma p-tau217 measure improves diagnostic confidence in patients with Alzheimer's disease versus syndromes associated with frontotemporal lobar degeneration

Cantoni V, Cotelli MS, Rota M, Alberici A, Libri I, Huber H, Tan K, Ghidoni R, Bellini S, Zetterberg H, Blennow K, Ashton NJ, Borroni B.

Alzheimers Dement. 2025 May;21(5):e70289. doi: 10.1002/alz.70289.

Amyloid-β Clearance with Monoclonal Antibodies: Transforming Alzheimer's Treatment

Fatima R, Khan Y, Maqbool M, Ramalingam PS, Khan MG, Bisht AS, Hussain MS.

Curr Protein Pept Sci. 2025;26(7):515-545. doi: 10.2174/0113892037362037250205143911.

Treatment-related amyloid clearance (TRAC): a framework to characterize patients in the era of anti-amyloid therapies

La Joie R, Cummings JL, Dage JL, Galasko D, Ikonomovic MD, Karikari TK, Landau SM, Llibre-Guerra JJ, Mummery CJ, Ossenkoppele R, Price JC, Risacher SL, Smith R, van Dyck CH, Carrillo MC.

Alzheimers Dement. 2025 Nov;21(11):e70997. doi: 10.1002/alz.70997.

Is the Era of One-Size-Fits-All Alzheimer's Treatment Officially Over?

Verma S, Kumari K, Kesharwani P, Verma K, Dwivedi J, Paliwal S, Sharma S.

J Mol Neurosci. 2025 Dec 22;76(1):3. doi: 10.1007/s12031-025-02445-1.

Effect of probiotics on cognitive function and cardiovascular risk factors in mild cognitive impairment and Alzheimer's disease: an umbrella meta-analysis

Xiao B, Fu L, Yang Z, Yu G.

J Health Popul Nutr. 2025 Apr 8;44(1):109. doi: 10.1186/s41043-025-00816-3.

Diverse role of S100 calcium-binding protein B in alzheimer's disease: pathological mechanisms and therapeutic implications

Sarkar S, Porel P, Kosey S, Aran KR.

Inflammopharmacology. 2025 Apr;33(4):1803-1816. doi: 10.1007/s10787-025-01697-y. Epub 2025 Mar 9.

Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer Disease

Grill JD, Tam S, Thai G, Vides B, Pierce AL, Green K, Gillen DL, Teng E, Kremen S, Beigi M, Rissman RA, Léger GC, Balasubramanian A, Revta C, Morrison R, Jennings R, Pa J, Zhang J, Jin S, Messer K, Feldman HH.

Neurology. 2025 Jan 14;104(1):e210152. doi: 10.1212/WNL.0000000000210152. Epub 2024 Dec 13.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias